UroGen Pharma (URGN) Finished Goods (2020 - 2021)

UroGen Pharma (URGN) posted quarterly Finished Goods of $888000.0 for Q1 2021, down 2.74% on a QoQ basis from $913000.0 in Q4 2020.

UroGen Pharma (URGN) Finished Goods (2020 - 2021) Analysis & Trends

UroGen Pharma (URGN) has reported Finished Goods for 2 consecutive years, with $888000.0 the latest figure, recorded in Q1 2021.

Quarterly Finished Goods changed N/A year-over-year to $888000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $888000.0 (changed N/A YoY) and the FY2020 annual result came in at $913000.0, changed N/A from the prior year.
Finished Goods retreated to $888000.0 in Q1 2021 per URGN's latest filing, from $913000.0 in the prior quarter.
Over the last five years, Finished Goods for URGN reached as high as $913000.0 in Q4 2020 and fell as low as $232000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	UroGen Pharma	2.13 Bn	1.99 Bn	46.82 Mn

Download Data